Orphazyme reports financial results in Interim Report First Half 2022 Company announcement Orphazyme A/S No. 36/2022 www.orphazyme.com Company Registration No. 32266355
Orphazyme Announces Publication of 2021 Financial Results and Annual Report Orphazyme A/SCompany announcement No. 30/2022 Annual reportwww.orphazyme.com Company Registration No. 32266355
Orphazyme announces update on in-court restructuring proceedings Orphazyme A/S in restructuring Company announcement No. 23/2022Inside information www.orphazyme.com Company Registration No. 32266355
Orphazyme to submit statutory restructuring plan to Danish court (NASDAQ:ORPH) Danish biotech firm, Orphazyme (ORPH) said it will submit the enclosed proposal for a statutory restructuring plan to the Danish Maritime and Commercial High Court and to its…
Orphazyme Withdraws European Application For Arimoclomol, Initiates Delisting Of Its ADSs Orphazyme A/S (NASDAQ: ORPH ) has decided to withdraw its European Marketing Application for arimoclomol for Niemann-Pick disease Type C (NPC) ahead of a final vote and opinion by the CHMP scheduled for later this month. "Today''s decision to withdraw the MAA enables us to consider the best possible path forward for arimoclomol," … Full story available on Benzinga.com
Orphazyme Withdraws European Application For Arimoclomol, Initiates Delisting Of Its ADSs Orphazyme A/S (NASDAQ: ORPH) has decided to withdraw its European Marketing Application for arimoclomol for Niemann-Pick disease Type C (NPC) ahead of a final vote and opinion by the CHMP scheduled for later this month. "Today's decision to withdraw the MAA enables us to.
Dear ORPH Stock Fans, Mark Your Calendars for March 31 After Orphazyme announced that it would withdraw the application for approval of its drug and delist its ADSs, ORPH stock is falling. The post Dear ORPH Stock Fans, Mark Your Calendars for March 31 appeared first on InvestorPlace.
Orphazyme announces withdrawal of European Marketing Authorisation Application for arimoclomol for the treatment of Niemann-Pick disease type C Orphazyme A/S Company announcement No. 13/2022Inside information www.orphazyme.com Company Registration No. 32266355
Orphazyme A/S has filed for voluntary delisting of ADSs Orphazyme A/S Company announcement No. 12/2022 www.orphazyme.com Company Registration No. 32266355